Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extention (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients with IgA Nephropathy Who Have Completed Study Nef-301 in China

NCT05534919 is registered in ClinicalTrials.gov with Everest Medicines (Singapore) Pte. Ltd. as lead sponsor.

NCT NCT05534919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05534919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extention (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients with IgA Nephropathy Who Have Completed Study Nef-301 in China
Lead sponsor
Everest Medicines (Singapore) Pte. Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 9, 2022
Completion date
July 17, 2024
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunoglobulin a nephropathy (igan)